Cited by 16Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo ESuita)

Yanagi, Koji, Yamashita, Shizuya, Hiraoka, Hisatoyo, Ishigami, Masato, Kihara, Shinji, Hirano, Ken-ichi, Sakai, Naohiko, Nozaki, Shuichi +5 more·1997·Atherosclerosis

Abstract

Apolipoprotein (apo) E7 was originally identified by Yamamura et al. in subjects with atherosclerotic cardiovascular diseases (J. Clin. Invest. 1984;74:1229). However, the lipoprotein abnormalities associated with apo E7 phenotype have not been elucidated. In the current study, to clarify the physiological roles of apo E7, lipoprotein abnormalities were studied in 12 apo E7 heterozygotes. A total of seven subjects were hyperlipidemic and five subjects were normolipidemic. The apo E phenotype was apo E7/3 in 11 subjects and apo E7/4 in one subject. Polymerase chain reaction revealed that all of the subjects with apo E7 phenotype had the same mutation as that of apo E(Suita) as reported previously (J. Biochem. 1989;105:249). All the hyperlipidemic subjects were over 40 years of age and two of them also had and severe coronary heart disease. Ultracentrifugal analysis revealed that the cholesterol level both in very low density lipoprotein and in intermediate density lipoprotein (IDL) was substantially higher in hyperlipidemic apo E7 heterozygotes, compared with control subjects and that the IDL cholesterol was also increased even in normolipidemic apo E7 heterozygotes. Polyacrylamide gel electrophoresis of lipoproteins showed a midband, which implies the increase of remnant lipoproteins, in 11 subjects out of 12, irrespective of the presence or absence of hyperlipoproteinemia. In two cases, a broad beta pattern was observed similar to that seen in type III hyperlipoproteinemia.…

Integrity signals

Registry

Crossref · 10.1016/s0021-9150(96)06068-6

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE2 Dunedin (Arg228Cys), APOE2 (Val236Glu), APOE7 Suita (Glu244,245Lys) (all heterozygotes), and APOE3 (Arg251 Gly, Cys112Arg) in the C-terminal domain were identified as variants that cause hypertriglyceridemia or CHL.

    “APOE2 Dunedin (Arg228Cys)121), APOE2 (Val236Glu)122), APOE7 Suita (Glu244,245Lys)123, 14) (all heterozygotes), and APOE3 (Arg251 Gly, Cys112Arg) 122) in the C-terminal domain were identified as variants that cause hypertriglyceridemia or CHL.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yanagi, K., Yamashita, S., Hiraoka, H., Ishigami, M., Kihara, S., Hirano, K.-I., Sakai, N., Nozaki, S., Funahashi, T., Kameda-Takemura, K., Kubo, M., Tokunaga, K., & Matsuzawa, Y.
Affiliations
  • Osaka University Hospital (JP)
  • The University of Osaka (JP)
Corresponding author
Yamashita, Shizuya
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
1997-05
Volume
131
Issue
1
Pages
49-58
ISSN
0021-9150 (ISSN-L)
OpenAlex
W2115354652
Cited by
16
References
7
Citations by year
2025: 1 · 2022: 2 · 2021: 2 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 1
FWCI
1.15
Type
journal article
Language
en
Open access
closed
Locations
  • Atherosclerosis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education, Culture, Sports, Science and Technology (3557117, 4404085)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
apolipoprotein E, remnant lipoproteins, hyperlipoproteinemia, intermediate-density lipoprotein cholesterol, VLDL cholesterol, type III hyperlipoproteinemia, dietary therapy, hyperlipidemia, coronary artery disease, obesity, aging, impaired glucose metabolism, lipoprotein metabolism
MeSH terms
Adult, Aged, Apolipoproteins E, Carrier Proteins, Cholesterol, DNA, Electrophoresis, Polyacrylamide Gel, Glycoproteins, Heterozygote, Humans, Hyperlipidemias, Lipoproteins, Middle Aged, Cholesterol, VLDL, Polymerase Chain Reaction, Apolipoprotein E3, Cholesterol Ester Transfer Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review